William Schwieterman

Biography

 Expert in the clinical development of a wide range of investigational therapeutic agents; spent 10 years as a Supervisor at the FDA and as a clinical reviewer on numerous biological and pharmaceutical-based agents including Enbrel, Remicade, Pegasys, Xigris and Zenapax; has written numerous FDA guidance documents; extensive input as consultant and advisory board member on multiple successful trials; led clinical development teams-including presentations at 3 positive advisory committee meetings-to achieving marketing approval of two drugs (pegloticase and droxidopa).   Dr. Schwieterman is a board-certified internist and a rheumatologist.

Research Interest

 Oncology